Trials / Terminated
TerminatedNCT01266005
A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a open, randomized, parallel study. Subjects will have Clevudine or Entecavir therapy for 48 weeks(Clevudine:Entecavir = 2:1), and subjects who have Complete Response(HBV DNA negative and ALT normal) will have follow-up period for additional 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine | 30mg,QD |
| DRUG | Entecavir | 0.5mg QD |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2013-08-01
- Completion
- 2014-01-01
- First posted
- 2010-12-24
- Last updated
- 2014-12-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01266005. Inclusion in this directory is not an endorsement.